Neurological disease and brain plasticity research gets major funding boost


Published: 19Mar2021

The Canada Foundation for Innovation supports innovative projects that tackle global challenges

Exciting initiatives involving researchers at The Neuro are among the latest getting support under The Canada Foundation for Innovation’s Innovation Fund competition.

Next Generation Dopaminergic Cell Modeling and Therapeutics for Movement Disorders, led by Carl Ernst at McGill University and Dr. Edward Fon of The Neuro and McGill University seeks a major breakthrough for people suffering from movement disorders, including Parkinson’s disease, as well as other neurodevelopmental, neurodegenerative, and genetic disorders. The project received more than $3.4 million from the CFI Innovation Fund. With additional funding, more than $8.5 million will be invested.

Robert Zatorre also received support for his collaboration with Université de Montreal’s Simon Dalla Bella, entitled Auditory-Motor Skill Learning and Brain Plasticity. Another Université de Montreal-led project, Neurodevelopmental basis of nervous system disorders: NeuroBasis, also involves Stuart Trenholm and Edward Ruthazer at The Neuro.

“Projects funded through the Innovation Fund help McGill remain at the forefront of exploration and innovation, while making meaningful contributions to generating social, health, environmental and economic benefits and addressing global challenges,” said Martha Crago, Vice-Principal (Research and Innovation) at McGill University.

Source: McGill Reporter


The Neuro logoMcGill logoMcGill University Health Centre logoKillam logo


Back to top